What is the primary clinical benefit of neoadjuvant chemotherapy in breast cancer?

• A. It increases overall survival compared with adjuvant therapy.
• B. It changes the timing of treatment and may permit breast-conserving surgery if the tumor shrinks.
• C. It reduces chemotherapy-related toxicity compared with adjuvant therapy.
• D. It eliminates the need for radiation therapy.

Answer: (B)

Neoadjuvant chemotherapy is given before surgery with the main goal of shrinking a tumor so surgery can be less extensive. By reducing tumor size, many patients become candidates for breast-conserving surgery (like lumpectomy) instead of a full mastectomy. This approach also lets clinicians treat micrometastatic disease earlier and assess how the cancer responds to systemic therapy.

It’s not primarily about boosting overall survival compared with starting chemo after surgery, and it doesn’t inherently reduce chemotherapy toxicity. Radiation therapy is still commonly required after breast-conserving surgery, so neoadjuvant treatment does not eliminate the need for radiation.